XORTX Therapeutics Inc (TSE:XRTX)
:XRTX
Want to see TSE:XRTX full AI Analyst Report?
XRTX Stock Chart & Stats
C$0.78
C$0.05(2.94%)
At close: 4:00 PM EST
C$0.78
C$0.05(2.94%)
Day’s Range― - ―
52-Week RangeC$2.43 - C$9.85
Previous CloseN/A
Volume514.00
Average Volume (3M)11.08K
Market Cap
C$4.04M
Enterprise ValueC$402.49K
Total Cash (Recent Filing)C$250.45K
Total Debt (Recent Filing)C$15.07K
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,392,444
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)C$3.25M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt reduces financial risk and preserves strategic optionality for a clinical-stage biotech. With minimal interest burden the company can focus capital on R&D or negotiate non-dilutive partnerships, improving the chance to fund trials or milestones without heavy fixed obligations.
Narrowing Operating LossesSubstantial reduction in operating losses signals durable improvement in cost structure or program spend discipline. Continued narrowing can extend runway, reduce future financing needs, and increase credibility with partners or investors when pursuing late-stage trials or commercialization strategies.
Focused Renal PipelineA concentrated clinical-stage focus on hyperuricemia and kidney disease targets a clear, large unmet medical need with defined regulatory pathways. Specialization can drive technical expertise, streamline R&D, and make the company an attractive partner for larger biopharma seeking renal assets.
Bears Say
No RevenueAs a development-stage company without product sales, XORTX lacks internal revenue to fund operations, leaving it dependent on external financing. Persistent net losses mean earnings quality is weak and long-term sustainability hinges on successful trials, partnerships, or capital raises rather than organic cash generation.
Persistent Cash BurnOngoing negative operating and free cash flow depletes liquidity and shortens runway unless offset by financing or partnerships. Persistent burn increases the likelihood of dilutive capital raises, constrains ability to fund multiple trials concurrently, and raises execution risk if funding windows narrow.
Shrinking Equity BaseA materially reduced equity cushion limits the company's ability to absorb setbacks and heightens refinancing risk. With thin shareholder equity, future capital needs are likelier to be met via dilutive financings or costly deals, which can impede long-term strategic flexibility and shareholder value preservation.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$2.42 and its highest was C$9.85 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$4.04M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 64 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -C$0.809 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.809.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,392,444 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.809 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20.288%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---